Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in μ-opioid receptor knockout mice

Neuropsychopharmacology

Volumn 29, Issue 9, 2004, Pages 1656-1663

  Ide, Soichiro ^a,b   Minami, Masabumi ^b   Satoh, Masamichi ^b   Uhl, George R ^c   Sora, Ichiro ^a,c,d   Ikeda, Kazutaka ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antinociception; Buprenorphine; Detoxification; Knockout mice; Opioid receptor; Reward

Indexed keywords

BUPRENORPHINE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR ANTAGONIST; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONDITIONING; CONTROLLED STUDY; DATA ANALYSIS; HOT PLATE TEST; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; TAIL FLICK TEST; WILD TYPE;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; CHO CELLS; CONDITIONING, OPERANT; CRICETINAE; CYCLIC AMP; DNA, COMPLEMENTARY; HEAT; HUMANS; MICE; MICE, KNOCKOUT; NALOXONE; NARCOTIC ANTAGONISTS; PAIN; PAIN MEASUREMENT; RADIOLIGAND ASSAY; REACTION TIME; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; REWARD;

EID: 4344698717     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300463     Document Type: Article

References (39)

1. Blake AD, Bot G, Freeman JC, Reisine T (1997). Differential opioid agonist regulation of the mouse mu opioid receptor. J Biol Chem 272: 782-790.
2. Bot G, Blake AD, Li S, Reisine T (1998). Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist. J Pharmacol Exp Ther 284: 283-290.
3. Cheskin LJ, Fudala PJ, Johnson RE (1994). A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 36: 115-121.
4. Comer SD, Collins ED, Fischman MW (2002). Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 301: 266-276.
5. Cowan A, Lewis JW, Macfarlane IR (1977). Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60: 537-545.
6. D'Amour F, Smith D (1941). A method for determining loss of pain sensation. J Pharmacol Exp Ther 72: 74-79.
7. Funada M, Suzuki T, Narita M, Misawa M, Nagase H (1993). Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 32: 1315-1323.
8. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N (2003). A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 179: 38-42.
9. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA et al (2003). Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28: 2000-2009.
10. Hoffman DC, Beninger RJ (1989). Preferential stimulation of D1 or D2 receptors disrupts food-rewarded operant responding in rats. Pharmacol Biochem Behav 34: 923-925.
11. Ikeda K, Ichikawa T, Kobayashi T, Kumanishi T, Oike S, Yano R (1999). Unique behavioural phenotypes of recombinant-inbred CXBK mice: partial deficiency of sensitivity to mu- and kappa-agonists. Neurosci Res 34: 149-155.
12. Ikeda K, Kobayashi T, Ichikawa T, Kumanishi T, Niki H, Yano R (2001). The untranslated region of (mu)-opioid receptor mRNA contributes to reduced opioid sensitivity in CXBK mice. J Neurosci 21: 1334-1339.
13. Iwamoto ET (1985). Place-conditioning properties of mu, kappa, and sigma opioid agonists. Alcohol Drug Res 6: 327-339.
14. Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y (1995). Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci 56: PL285-290.
15. Kamei J, Sodeyama M, Tsuda M, Suzuki T, Nagase H (1997). Antinociceptive effect of buprenorphine in mul-opioid receptor deficient CXBK mice. Life Sci 60: PL333-PL337.
16. Katsumata S, Minami M, Nakagawa T, Iwamura T, Satoh M (1995). Pharmacological study of dihydroetorphine in cloned mu-, delta- and kappa-opioid receptors. Eur J Pharmacol 291: 367-373.
17. Kieffer BL (1999). Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20: 19-26.
18. Leander JD (1988). Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol 151: 457-461.
19. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L (2002). A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 97: 1395-1404.
20. Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN (1998). mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 54: 321-326.
21. Longoni R, Cadoni C, Mulas A, Di Chiara G, Spina L (1998). Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC 80: 2. Place-preference and brain microdialysis studies in rats. Behav Pharmacol 9: 9-14.
22. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W et al (2003). Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23: 10331-10337.
23. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the muopioid-receptor gene. Nature 383: 819-823.
24. Matthes HW, Smadja C, Valverde O, Vonesch JL, Foutz AS, Boudinot E et al (1998). Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci 18: 7285-7295.
25. Mello NK, Lukas SE, Bree MP, Mendelson JH (1988). Progressive ratio performance maintained by buprenorphine, heroin and methadone in Macaque monkeys. Drug Alcohol Depend 21: 81-97.
26. Neilan CL, Akil H, Woods JH, Traynor JR (1999). Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists. Br J Pharmacol 128: 556-562.
27. Pick CG, Peter Y, Schreiber S, Weizman R (1997). Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Brain Res 744: 41-46.
28. Sante AB, Nobre MJ, Brandao ML (2000). Place aversion induced by blockade of mu or activation of kappa opioid receptors in the dorsal periaqueductal gray matter. Behav Pharmacol 11: 583-589.
29. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A et al (1998). Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17: 886-897.
30. Skoubis PD, Matthes HW, Walwyn WM, Kieffer BL, Maidment NT (2001). Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice. Neuroscience 106: 757-763.
31. Sora I, Elmer G, Funada M, Pieper J, Li XF, Hall FS et al (2001). Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 25: 41-54.
32. Sora I, Funada M, Uhl GR (1997a). The mu-opioid receptor is necessary for [D-Pen2,D-Pen5]enkephalin-induced analgesia. Eur J Pharmacol 324: R1-2.
33. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM et al (1997b). Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94: 1544-1549.
34. Tejwani GA, Rattan AK (2002). The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat. Anesth Analg 94: 1542-1546.
35. Tzschentke TM (1998). Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56: 613-672.
36. Winger G, Woods JH (2001). The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. Drug Alcohol Depend 62: 181-189.
37. Woolfe G, MacDonald A (1944). The evaluation of the analgesic action of pethidine hydrochloride (demerol). J Pharmacol Exp Ther 80: 300-307.
38. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP et al (1999). Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24: 243-252.
39. Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM et al (2000). Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 23: 326-334.